Innoviva Inc
INVAHealthcare|Biotechnology|USA
$22.23
+0.04 (+0.20%)
DCF (FCF)
$42.29
Tangible Book
$15.56
Graham Number
$41.06
Earnings Power
$26.78
About
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Stock Price
+16.6%(1Y)
Pipeline Summary
6 total trials1
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
Recruiting: 3ENROLLING_BY_INVITATION: 1Active: 1NOT_YET_RECRUITING: 1
Active Trials (4)
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
NCT06794541Complicated Intra-abdominal Infections (cIAI)
Phase 2Recruiting
Enrollment: 35 participants
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
NCT06801223Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Phase 1Recruiting
Enrollment: 48 participants
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
NCT06746883Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Recruiting
Enrollment: 100 participants
Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance
NCT07568275Septic Shock
Early P1Active
Enrollment: 30 participants
BioScore
4.2/10
Cautious
Ownership
Recent Insider Trades
DENNER ALEXANDER JSELL
2025-03-061,618,295 shares @ $17.55
Zhen MarianneSELL
2023-11-1510,994 shares @ $13.99
DENNER ALEXANDER JBUY
2023-06-1562,000 shares @ $13.13
DENNER ALEXANDER JBUY
2023-06-0615,000 shares @ $13.05
DENNER ALEXANDER JBUY
2023-05-30200,000 shares @ $13.04
Recent News
2026-06-22 21:30:38
2026-06-18 13:00:27
2026-06-18 12:32:57
2026-06-16 13:02:20
Data last updated: Jul 12, 2026, 07:39 PM